Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ASEAN Makes Slow But Steady Progress Toward Harmonization Of Pharmaceutical Regulations

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - The Association of Southeast Asian Nations is slated to implement common technical documents starting this year as part of "harmonized" pharmaceutical regulations in the region, which could benefit consumers by 2010

You may also be interested in...



Common Language For Regulatory Harmonization Takes Shape In Asia, But Mutual Recognition Unlikely Anytime Soon

Regulators, industry and health care agencies are increasingly using the same language to describe efforts at harmonization for drug approvals and manufacturing. But even though mutual recognition agreements on drug approvals are the “ultimate goal,” getting there in Asia could take a decade or more.

Would New Drug Launches Speed Up With A Pan-Asia Regulatory Framework? - Biopharma Asia Conference

SINGAPORE - As diseases like diabetes and cardiovascular complications - previously believed to be more prevalent in Western nations - are progressively spreading East to places like India and China, Asia-based pharmaceutical companies are pushing for a pan-Asian regulatory regime that can benefit its people with clear and obtainable goals

Would New Drug Launches Speed Up With A Pan-Asia Regulatory Framework? - Biopharma Asia Conference

SINGAPORE - As diseases like diabetes and cardiovascular complications - previously believed to be more prevalent in Western nations - are progressively spreading East to places like India and China, Asia-based pharmaceutical companies are pushing for a pan-Asian regulatory regime that can benefit its people with clear and obtainable goals

Related Content

UsernamePublicRestriction

Register

LL038093

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel